Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Madmanmadoxon Mar 20, 2018 2:36pm
125 Views
Post# 27748206

RE:Market correction/ crash

RE:Market correction/ crashI often think about this with small caps. What I do is map out the risk drivers of the return for the stock. Is Beta (Systematic Risk) driving the return? Debt? Expected growth? A contingent litigation event? Muiltples shrinking due to an increase in interest rates (due to inflation) should effect growth stocks the most since the discount rate increases which decreases the terminal value expectation in NPV valuations.  P/E ratios tend to decrease overall given the relative risk return tradeoffs between asset classes (Equity vs Tbills Vs Bonds) changes in increasing interest rate environments. What I also look at is Debt & Interest Expense/EBITDA and how that looks for every 25 basis increase in interest rates. I also look at how well can the company pass on inflation to the customer or will its margins compress as COGS rises?

ATE's value in this specific case (in my opinion) is being driven by partnership value or binary events. This is to say it is not immune to Beta market risk (as its proposective partner's likely will be effected) but it is less directly influenced and somewhat (at least relatively) mitigated. That is, my take anyway, market risk is less of a driver of returns for ATE relative to most positions you would likely be comparing it to. It will still effect the discount rate when discounting what a partner will pay but the driver of the return (and therein risk) for ATE shareholders will be can you negotiate a strong partnership deal based on the results of this 2B or not?
Bullboard Posts